GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
GlaxoSmithKline plc
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
Price(s) and
volume(s)
Price(s)
Volume(s)
£16.285
66.756 (personal contribution)
83.723 (personal contribution)
165.304 (personal contribution)
165.315 (personal contribution)
66.756 (matching shares)
83.723 (matching shares)
165.304 (matching shares)
165.315 (matching shares)
d)
Aggregated information
Aggregated volume Price
1,263.154
e)
Date of the transaction
2016-07-14
f)
Place of the transaction
n/a